Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 21;75(Suppl 4):S541-S548.
doi: 10.1093/cid/ciac716.

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

Stanley E Cooper  1 , Joshua Rosenblatt  1 , Roy M Gulick  1
Affiliations
Review

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

Stanley E Cooper et al. Clin Infect Dis. .

Abstract

Long-acting injectable antiretroviral therapy (LAI-ART) for the treatment and prevention of human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by offering an alternative to daily oral medication. However, significant challenges at the drug, patient, and system levels risk impeding the uptake and implementation of LAI-ART. This review aims to describe the known and anticipated barriers to uptake of LAI-ART in high-income countries, as well as the ongoing research addressing some of these barriers to improve the delivery and uptake of LAI-ART products.

Keywords: HIV-1; antiretroviral therapy; cabotegravir; long-acting injectable antiretroviral; preexposure prophylaxis; rilpivirine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. E. C. reports research training funding from the National Institutes of Health (NIH) through grant number T32AI007613. R. G. reports research funding from an NIH UM1 grant for HIV clinical trials; royalty payments from Elsevier for a textbook chapter on HIV therapy; and payments for educational talks at academic and non-profit institutions. J. R. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. CDC . Ending HIV transmission-test, treat, and prevent, 2019. Available at:https://cdc.gov/nchhstp/newsroom/2019/ending-HIV-transmission-test-treat.... Accessed 15 March 2022.
    1. Martin M, Del Cacho E, Codina C, et al. . Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263–8. - PubMed
    1. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. . Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020; 382:1112–23. - PubMed
    1. Swindells S, Lutz T, Van Zyl L, et al. . Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS 2022; 36:185–94. - PMC - PubMed
    1. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. . Long acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med 2020; 382:1124–35. - PubMed

Publication types

Substances